Track topics on Twitter Track topics that are important to you
A new Nature paper has described a first-of-its-kind mathematical model for predicting how a cancer patient will benefit from checkpoint inhibitors, a class of drugs that includes Merck’s Keytruda and Bristol Myers-Squibb’s Opdivo.
Original Article: Can a math model help predict an immune response to cancer?NEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...